SARS-CoV-2 IgG antibody responses in New York City

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a strain of coronavirus that causes coronavirus disease 2019 (Covid-19) and has been declared a global pandemic by the World Health Organization. Total cases of SARS-CoV-2 worldwide exceed 10.2 million, with over 503,000 deaths recorded...

Descripción completa

Detalles Bibliográficos
Autores principales: Reifer, Josh, Hayum, Nosson, Heszkel, Benzion, Klagsbald, Ikey, Streva, Vincent A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2020
Materias:
Virology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372255/
https://www.ncbi.nlm.nih.gov/pubmed/32777699
http://dx.doi.org/10.1016/j.diagmicrobio.2020.115128
Descripción
Sumario:Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a strain of coronavirus that causes coronavirus disease 2019 (Covid-19) and has been declared a global pandemic by the World Health Organization. Total cases of SARS-CoV-2 worldwide exceed 10.2 million, with over 503,000 deaths recorded. Little is known about the body's immune response to SARS-CoV-2 infection. In this paper, we describe SARS-CoV-2 IgG antibody responses in 28,523 patients from the New York City metropolitan area and report a SARS-CoV-2 IgG positivity rate of 44%, indicating the widespread nature of the pandemic in the city and state of New York. Additionally, for a subset of patients, we report on the correlation between SARS-CoV-2 patient symptom severity and level of SARS-CoV-2 IgG antibody found in the patient sample.

Ejemplares similares